Creo Medical Reports 50% Revenue Growth Amid Cost Reductions

Creo Medical (LSE:CREO) reported full-year 2025 revenue of £6m, a 50% year-over-year increase driven by growing clinical adoption of its Advanced Energy endoscopy technology. Simultaneously, the company reduced underlying operating costs by 20%, which narrowed the underlying operating loss by more than 40%. This operational progress marks a distinct shift from pure technology development toward active commercialisation, a key metric for investors evaluating the company's trajectory.

Momentum has carried into the first half of 2026, with revenue rising 45% to £3.2m. During this period, the underlying operating loss decreased by over 25% to £4.9m. Management attributes this improvement to a stronger order book and strategic expansion into new geographic markets, including Latin America. The company projects full-year 2026 revenue growth between 50% and 60%, sustained by increased procedure volumes and market penetration.

Partnerships Accelerate Technology Integration

Creo’s Kamaptive programme facilitates the integration of its energy platform into third-party medical systems, including robotic-assisted surgical units. The company has secured an agreement with a major global medtech partner for initial integration. This licensing approach allows Creo to expand its procedural reach without bearing the capital costs of building a proprietary distribution network, potentially scaling revenue more efficiently than direct sales.

Manufacturing Outsourcing Reduces Cost Base

To improve margins, Creo is outsourcing manufacturing operations. Management expects this strategic move to reduce the underlying operating cost base by approximately 15% compared to 2025 levels. By decoupling revenue growth from fixed cost increases, the company aims to generate operating leverage that brings the business closer to profitability while maintaining its lean structure.

Cash Reserves Limit Near-Term Risk

As noted by GN stocks/shares-surge, the stock remained flat over the past year as investors awaited tangible commercial results. Creo ended June with £7.4m in cash, providing a buffer against near-term funding needs. However, the company remains loss-making, and any significant slowdown in clinical adoption or unexpected capital requirements could pressure sentiment. The current financial position supports the upcoming growth phase but leaves little margin for prolonged operational inefficiency.